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Introduction

Central Nervous System and Neuro-Degenerative Diseases
The nervous system is the body’s biological information highway. It sends and receives
information through electrical signals to control all the biological processes and movements in the
body. It is anatomically divided into two systems: central nervous system (CNS) and peripheral
nervous system (PNS). The CNS is composed of the brain and the spinal cord and is responsible for
receiving and interpreting signals from the PNS, while the PNS is made of all other nerves that
travel to and from the CNS to tissues and organs. The consequences of an organ receiving a signal
through the nervous system depend on the physiological function of the organ itself. For example, a
signal sent to a muscle will result in either contraction or relaxation depending on the type of
muscle and a signal received by a gland can result in an increase or decrease in secretion.
Neurodegenerative diseases are a group of diseases characterized by continuous neuronal
degeneration or cell death within a specific area of the nervous system, eventually leading to
damage and consequently loss of function of that part of the nervous system and the structures
innervated by the affected area. A common feature of this group of diseases is an increased level
of oxidative stress, which is perhaps responsible for the death of a specific neural cell population.
The most common neurodegenerative diseases are Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease and Amyotrophic Lateral Sclerosis (ALS), their location and most
prominent macro- and micro-symptoms are described in Figure (1).
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Figure 1: Most common neurodegenerative diseases, their location within the CNS, and the most
prominent accompanying macro- and micro-symptom for each (Bertram and Tanzi. JCL, 2005).

Parkinson’s Disease
Parkinson’s disease was first described by the British physician James Parkinson. He
described it as “shaking palsy” in his monograph An Essay on the Shaking Palsy (1), which
included his observations of six patients. Further understanding of the signs and symptoms of
Parkinson’s disease was undertaken later by professor Jean-Martin Charcot. In 1912, around 100
years after the first description of Parkinson’s disease by Dr. James Parkinson, the German
neurologist Friedrich Lewy described the main pathological biomarker of the disease, Lewy
Bodies (2). Although we are approaching the 200-year anniversary of the first scientific
diagnosis of Parkinson’s and the 100-year anniversary of the first diagnosis of Lewy Bodies

2

lesions in a Parkinson’s patient, still many questions are yet to be answered to improve the
diagnosis and management of the disease.
The prevalence of Parkinson’s disease in the general population at age 65 is approximately
1%, and it increases to approximately 5% by age 85 (3,4). Parkinson’s disease is considered the
second most common neurodegenerative disease after Alzheimer’s disease (3,4). Although the
mean age for the diagnosis of Parkinson’s disease is during the 6th decade of life, symptoms
usually start years before clinical diagnosis and go unnoticed until more severe signs present (5).
Only around 3% of Parkinson’s cases are diagnosed before the age of 50 (4). The mean time
between diagnosis of Parkinson’s disease and death is 15 years, during which the disease
progress slowly (6,7). The main symptoms of Parkinson’s disease include bradykinesia (slow
movement), muscular rigidity (increased tone), and gait impairment (7). Together, these clinical
symptoms are called Parkinsonism Syndrome. Although several neurodegenerative diseases
could cause Parkinsonism Syndrome, the main cause is Parkinson’s disease. The main
pathophysiological picture behind Parkinson’s disease is the neurodegeneration of dopaminergic
neural cells in the Substantia Nigra pars compacta, which leads to dysfunction of the basal
ganglia, which function in the initiation and execution of voluntary movement. The symptoms of
Parkinsonism Syndrome as a consequence of degeneration of the basal ganglia start developing
gradually as the neurodegeneration progress (8). In the last 10 years, therapeutic agents have
been available on the market to manage the symptoms of Parkinson’s disease, the most effective
is dopamine replacement therapy that aims at restoring dopamine levels in the affected part of the
brain (7). However, none of the available therapeutic solutions, including dopamine replacement
therapy, have been proven to revert or stop the pathophysiological dysfunction and neural
degeneration behind the disease. Instead, delaying symptoms development and prolonging life
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expectancy are the maximal possible benefits shown to be gained from the currently available
therapeutic agents.

Protein Biosynthesis and Oxidative Folding of Proteins
Protein biosynthesis is the process of synthesizing new proteins within biological cells. New
proteins are continuously being synthesized to compensate the cells that have been lysed or
exported. The process of protein biosynthesis consists of multiple steps including transcription
and translation of mRNA, post-translational modifications, and protein folding.
Transcription is the process of synthesizing new mRNA molecules from the double-stranded
DNA molecule (Figure 2). The process is complex and it involves temporary unwinding of the
region carrying the gene within the double stranded DNA. The unwinding (sometimes called
unzipping) occurs through a group of enzymes called Helicases. This process aids in creating
sufficient space for proteins and molecules involved in the transcription process to carry on and
consequently for the transcription process to occur. Many proteins are involved in the regulation
of the transcription process, such as transcription factors, which are sometimes called sequencespecific DNA binding factors, and co-activators, which increase gene expression by binding to
transcription factors. RNase is the enzyme responsible for reading the DNA template strand and
synthesizing the complementary mRNA sequence. The enzyme reads the template DNA
sequence from 3-prime to 5-prime end, and the complementary mRNA is synthesized in the
opposite direction, from 5-prime end to 3-prime end.
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Figure 2: Transcription of mRNA from DNA template. The newly synthesized mRNA strand is
complementary to the template DNA strand, after substitution of Thymine (T) bases with Uracil (U)
(Pearson Education Inc., 2012).

During translation, tRNA molecules are loaded with single amino acids, an amino acid per
tRNA molecule. Then, loaded tRNA molecules are matched up through their anti-codon regions
with the complementary three-bases codon region in the mRNA molecule that encodes for the
protein to be synthesized. Both tRNA molecules and mRNA are brought together by ribosomes,
which are large and complex intracellular molecules made up of rRNA strands combined with
more than 50 different proteins (Figure 3). There are two different ribosomal subunits: large and
small. The large subunit is responsible for binding the newly added amino acid to the growing
polypeptide chain, while the small subunit is responsible for reading the mRNA codon encoding
for that amino acid.
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Ribosomal
subunit

Figure 3: Translation of mRNA strand into a polypeptide chain, namely the primary structure of
proteins. Since ribosomes are key in the assembly of amino acids together, the whole process occurs in the
rough endoplasmic reticulum which is rich in ribosomes (Purves et al., 1994).

Posttranslational modifications are a group of chemical and physical modifications of the
newly synthesized polypeptide chain that occur not only after the synthesis of the polypeptide
chain is complete, but also during translation. Posttranslational modifications were found to be a
part of protein biosynthesis process in eukaryotes, but not prokaryotes. These modifications are
essential for the proper folding of the newly-synthesized polypeptide chain to form the proper
secondary and tertiary protein native needed for proper function. Examples of these
modifications are the addition of new functional groups such as acetyl and alkyl groups,
changing the chemical nature of some amino acids such as converting Asparagine to Aspartic
acid or Glutamine to Glutamic acid, the breakage of an existing bond between two amino acids,
and the formation of a new bond between two amino acids.
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One of the most common examples of posttranslational modifications is the formation of a
disulfide bond between two Cysteines (Figure 4). Examples of proteins that have disulfide bonds
in their native structure include immunoglobulins, digestive enzymes, albumin, and polypeptide
hormones. In fact, most of proteins destined for plasma membrane and extracellular proteins
contain disulfide bonds in their native structure. Oxidative protein folding is the process by
which proper disulfide bonds, which are essential for the formation of the native tertiary
structure, are formed (29-32). Oxidative protein folding is a complex process, because it is a
combination of physical conformational folding and the chemical formation of native disulfide
bonds (29-31). Moreover, formation of non-native disulfide bonds during the oxidative folding
process requires further chemical thiol-disulfide exchange reactions to exchange non-native
disulfide bonds for the native bonds which eventually leads to a competition between the
physical conformational changes of the oxidative protein folding process and the chemical thioldisulfide bond exchange (29-32). This competition is unique to proteins that have disulfide bonds
in their native structure (33). Disulfide bond formation in these types of proteins and protein
folding occur in the endoplasmic reticulum (ER) where the oxidized:reduced glutathione ratio is
favorable for the oxidative folding to proceed. Within the ER, the ratio of reduced glutathione
(GSH) to oxidized glutathione (GSSG) ranges between 1:1 and 3:1. However, in the cytosol, the
ratio increases to 30:1, which makes a highly reductive environment that is not favorable for the
oxidative folding and maturation of the nascent polypeptide chain into the tertiary structure.
Protein traffic in the endoplasmic reticulum at any moment includes mainly three types of
proteins: properly-folded native-structured proteins that are biologically functional and to be
secreted to the cell membrane or outside the cell, terminally misfolded proteins to be secreted to
the cytosol for proteosomal degradation, and newly synthesized polypeptides still to be folded (911). Properly folded proteins are secreted outside the endoplasmic reticulum via the secretory
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pathway, while terminally misfolded proteins are excreted via the translocatory pathway. A
major determinant of whether proteins will be secreted through the secretory pathway or the
translocatory pathway is the ability of the newly synthesized protein to rapidly acquire its native
disulfide bonds during the oxidative folding process (12-14). Beside the favorable oxidative
environment within the ER, many other cofactors and chaperones play important roles assisting
the oxidative folding process. Among these is Protein Disulfide Isomerase (PDI) (Figure 5). PDI
is the chief endoplasmic reticulum resident oxidoreductase chaperone. It catalyzes proper folding
of disulfide bond containing proteins within the endoplasmic reticulum during the oxidative
folding process (9,15). Therefore, optimally functioning PDI is critical for keeping the
homeostasis between newly synthesized polypeptides and folded secretory proteins, and
consequently for preventing the overburden of the translocatory pathway (10,11). Overburdening
of the translocatory pathway results in aggregates of protein such as the Lewy bodies seen in
Parkinson’s disease and β-amyloid in Alzheimer’s.

Figure 4: Disulfide bond between two Cysteine residues. The two Cysteines could be either within the
same polypeptide chain or two different chains.
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Figure 5: Schematic of protein disulfide isomerase (PDI) indicating the redox-active a and a0 domains
and the hydrophobic b and b’ domains (Gonzalez et al., 2010).

PDI works mainly through two different mechanisms: oxidation and isomerization. In both
mechanisms, molecular oxygen is the terminal electron acceptor (15). The chaperone consists of
five domains, two of which are responsible for its activity. These two domains contain surface
exposed Cysteine residues that are responsible for both oxidoreductase and thiol-disulfide
isomerize activities of PDI (16-19). Therefore modification or blockage of Cysteine affects PDI’s
ability to function properly. Involvement of these Cysteines in PDI’s activities does not affect its
structure (17-18). It was shown that intracellular high levels of nitrosative stress leads to
nitrosylation of redox-active Cysteines in PDI molecules, leading to their blockage (20-26). This
leads to the formation of S-nitroso-PDI, in which the two active domains are unable to oxidize
thiol groups or isomerize thiols-disulfide bonds in nascent polypeptides during the oxidative
folding process (27,28). S-nitroso-PDI were found to be abundant in isolated neural cells of
Parkinson’s Diseases and Alzheimer Disease patients (27,28). When further research was
done to investigate the correlation between these neurodegenerative diseases and nitrosylation of
PDI, it was found that the formation of N-nitroso-PDI leads to the accumulation of alphasynuclein and synphilin-1, the two major components of Lewy Bodies in the cytosol (36-39).
However, since these two proteins do not contain disulfide bonds, and consequently are not PDI
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substrates, it was concluded that there is a cross-talk between folding events within the ER and
aggregation of terminally misfolded protein within the cytosol (40). The cross-talk was
hypothesized to occur as follows: reduced catalytic activity of PDI compromised its capacity to
process newly synthesized protein and forward them to the secretory pathway. This has led to
overwhelming in the translocatory pathway caused by PDI substrate proteins (32, 34-35). The
traffic caused by these proteins overburdens the capacity of the cytosolic housekeeping
machinery (Parkin:Ubiquitin system), exceeding its capacity to tag terminally misfolded proteins.
Meanwhile, high-tend-misfold proteins such as alpha-synclein, synphilin-1 and A-beta, that need
to be ubiquitin-tagged in a timely manner, remain untagged. This result in failure of proteosomal
degradation of these aggregates and eventually neural cells undergo apoptosis and result in
neuropathies such as Parkinson’s disease and Alzheimer’s (32, 34-35, 40). These findings made
PDI of particular interest for managing these two diseases, probably along with other
neurodegenerative diseases that might have the same pathophysiology involved (27,28).

Many of the disulfide bond containing proteins have been used for research purposes both invitro and in-vivo to study the oxidative folding process of these protein in the ER over the last
three decades (40-72). Some of these include hirudin, tick anticoagulant, BPTI and bovine
ribonucleaseA (RNase). Using BPTI as a model for protein folding, researchers were able to
show the presence of intermediates between the fully reduced structure and the native structure of
BPTI using dithiothreitol-ox/dithiothreitol-red for oxidative folding process (40). Others used
bovine pancreatic ribonuclease A (RNase A) as a model for oxidative folding of proteins, and
using both GSSG/GSH and dithiothreitol-ox/dithiothreitol-red agents they were able to
demonstrate different pathways of folding of these proteins (40-46). In our research, we chose
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to use RNase (Figure 6) (82) as a model for disulfide bond containing proteins folding, not only
because of the wide variety of studies that have been done on the enzyme making it a very well
defined protein both chemically and physically, but also because of its unique properties in
exhibiting many different pathways through which it folds to the native structure. This makes
RNase A a reliable representative of the different features that exist in the oxidative folding
landscape of the disulfide bond containing protein pool. The typical oxidative folding pathway of
RNase A is shown in Figure 7 (39). For redox reactions, we are using dithiothreitolox/dithiothreitol-red reagent. The main problem with using of GSSG/GSH as a redox reagent is
the formation of mixed disulfide intermediates between the redox reagent and thiols in the
protein. These adducts complicate the HPLC analysis of protein fractions by adding up to the
total number of intermediates being formed during the oxidative folding process (48).
Dithiothreitolox/dithiothreitol-red redox agent does not form mixed disulfide intermediates with
protein thiols, and hence does not increase the number of intermediates formed (48). Also, since
dithiothreitolox is a weaker oxidizing agent than GSSG, using it has the advantage of giving a
greater control over the rate of the oxidative folding process (47,49).
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Narayan et al., 2000

Figure 6: Structure of bovine pancreatic ribonuclease A (RNase A) (79) a small but stable protein of
124 residues with four disulfide bonds: 26-84, 40-95, 58-110, and 65-72. The disulfide bonds 58-110 and
26-84 are fully buried in the major and minor hydrophobic cores, respectively. By contrast, the disulfide
bonds 65-72 and 40-95 occur near the surface of the protein, although the 65-72 disulfide bond is part of a
small hydrophobic core involving residues Val63, Ile107, Ala122, and Val124. The relatively large
number of Cysteines (eight) makes the oxidative folding of RNase A one of the most complex ever
studied; there are 7193 possible disulfide species, if mixed disulfide species are considered. The wellstudied conformational folding of disulfide-intact RNase A (80,81) aids in structural interpretations of
oxidative folding experiments (Narayan et al., 2000).
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Narayan et al., 2000

Figure 7: Oxidative folding pathway of RNase A at pH 8 (25°C) [48-53]. Unstructured isomer
ensembles of disulfide-bond-containing intermediates populate the pathway and achieve a quasiequilibrium status prior to the formation of structured intermediates. The blue lines within the image
represent protein’s native disulfide bond connectivities; black lines are non-native linkages; red lines are
thiolates. The values within brackets are the theoretically predicated numbers of isomers within each
ensemble when dithiothreitol (DTT) is used as a redox couple. Two major pathways and two minor
pathways of regeneration are depicted from the 3S and 2S ensemble, respectively (discussed in the text)
(Narayan, 2012).
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Materials and Method

Chemicals and reagents
RNase A and ellagic acid were purchased from the Sigma Chemical Co. They were tested for
purity by reversed phase HPLC analysis, and were found to be >99% pure. They were used
without further purification. Ferrious sulfate and hydrogen peroxide (30%) were purchased from
the Sigma Chemical Co. Reduced dithiothreitol (DTTred) was purchased from the Fisher
Scientific Co. Oxidized dithiothreitol and tetranitromethane were purchased from the Sigma
Chemical Co. and used without further purification. All other chemicals were of the highest
commercially available grade.

Preparation of fully reduced RNase A
Fully reduced RNase A was prepared by incubating the native protein (5mg/ml) in 9 M Urea
and 20 mM DTTred (PH 8, 200 mM Tris-HCL, 1 nM EDTA) for a period of 2 hours (83). The
pH was then dropped to 3 by adding 10 µL/ml acetic acid to the mixture. The mixture was then
dialyzed three times against 50 mM acetic acid. Each dialysis was done for 4 hours at 4°C,
before the dialysis solution is exchanged with a fresh one. The mixture was then desalted on a G25 column using 0.1% Glacial acetic acid as a mobile phase. The desalted fully reduced protein
was then kept in -80°C until further use.
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Oxidative folding of fully reduced RNase A.
Oxidative folding of previously fully-reduced RNase A was done by incubating fully reduced
RNase A (50 nM) with 100 mM DTTox (PH 8, 200 mM Tris-HCL, 1 mM EDTA, 25°C).
Time was recorded, and aliquots were periodically withdrawn every 3 hours from the
regeneration mixture. Aliquots were subjected to reduction pulse (2 mM DTTred for 1 min) (84),
then the pH was decreased to 3 by addition of 40 µL/ml glacial acetic acid. Aliquots were then
desalted using a
G-25 column and then dialyzed with reversed phase HPLC using a C-18 column (Supleco
Discovery® BIO Wide Pore C18, 5 µm, 25 cm * 4.6 mm). Acetonitrile gradient (1%/min) was
used as a mobile phase (85).

Oxidative folding of fully reduced RNase A under nitrosative and oxidative stress.
In other experiments, oxidative folding of fully reduced RNase A was done as described
above but after incubating the regeneration mixture with tetranitromethane (10 µM final
concentration by dilution of a stock of 2 mM acetonitrile solution). In other experiments,
oxidative stress environment was created by adding 5 µl/ml of freshly prepared mixture of 1:2
ferrous sulfate to hydrogen peroxide (1 mM : 2 mM) solution in acetonitrile. Aliquots withdrawal
and analysis was done as above.
In other experiments, ellagic acid (100 µM final concentration) was introduced to the
regeneration mixture before the addition of tetranitormethane. The same was repeated and ellagic
acid was added to the regeneration mixture before the addition of ferrous sulfate-hydrogen
peroxide mixture. Aliquots withdrawal and analysis was done as above.
The regeneration rate of the native structure of RNase A (N) from the fully reduced structure
(R) was determined by integrating the areas under the peaks corresponding to the native
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structure, the fully reduced structure, and structured intermediates at each time point. The
fractional increase of the native structure was plotted against time. The plotted data were fitted to
a single-exponential function and the rate constant was calculated for the regeneration process
(37, 86).

NOx scavenge assays and Mass Spectroscopy.
Ellagic acid (final concentration of 1 mM obtained by dissolving the neat compound) was
dissolved in ethyl acetate before adding tetranitromethane (final concentration of 1 mM, obtained
by diluting the neat compound). Incubation was done for 24 hours, and then ethyl acetate was
evaporated using rotor evaporator (80°C). The solid remaining layer was then dissolved in
methanol and subjected to ESI-FTMS (LTQXL, Thermo Fisher Scientific, San Jose, CA).
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DPPH (1,1-diphenyl-1-picrylhydrazyl) assay
Introduction.
DPPH antioxidant assay was first demonstrated in 1958 by Blois. He was able to demonstrate
the ability of DPPH molecule to accept hydrogen atom from a Cysteine molecule (89). However,
it was not until the late 80s that DPPH started drawing attention for characterizing the
antioxidant properties of different compounds (90). 1,1-diphenyl-1-picrylhydrazyl is a kind of
stable radical. It has an unpaired valence electron at one atom of nitrogen bridge (91). DPPH
antioxidant assay is used worldwide for the quantification of radical-scavenging capacity. It is
considered one of the most standard and easiest colorimetric assays used for evaluation of the
antioxidant properties of pure compounds. The higher the capacity of the compound to scavenge
the DPPH radical, the stronger it’s antioxidant ability. DPPH radical is stable in solution and it
has a purple color that absorbs at 517 nm in methanol. The mechanism behind DPPH antioxidant
assay is the scavenging of DPPH radical by the antioxidant to be tested (91). When DPPH
accepts a hydrogen atom from the antioxidant molecule, this results in the reduction of DPPH
into DPPH2, which has a yellow color (Figure 8) (88). The change from DPPH to DPPH2, and
consequently from purple to yellow, is accompanied by a reduction in absorbance at 517 nm
(Figure 9) (87). Using spectrophotometric measurements, antioxidant properties of compounds
being tested can be quantified. The original DPPH assay procedure has been modified throughout
the last three decades by many different labs for convenience. Table 1 shows different
modifications on DPPH assay protocol that have been adopted by different labs (92). These
modifications included variation in DPPH concentration (22.5-250 µM), incubation time (5-60
min), pH of the reaction mixture (3.0-5.5), and the solvent used (ethanol or methanol).

17

Figure 8. The reaction of DPPH free radical with antioxidant. AH is donor Molecule, and A* is free
radical produced (Musa et al., 2013).

Figure 9: Absorption spectra of DPPH and oxidation of DPPH radicals (Tam, 2012).
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Table 1: Summary of some representative publications of antioxidant assay using DPPH (Sharma et al.,
2009)

Materials and method:
DPPH assay procedure and data analysis were done in collaboration with Dr. Rachid Skouta,
University of Texas – El Paso. DPPH, ascorbic acid and ferrostatin-1 were purchased from
Sigma Chemicals Co. and used without further purification. All other chemicals were of the
highest commercially available grade. A TECAN M200 microplate reader was used for UV
readings. A 20X solution of DPPH was prepared by dissolving 3.9 mg of DPPH in 10 ml of
methanol (final concentration of 1 mM). Vortex and ultra-sonic waves were used for full
solubilization. The 20X DPPH solution was diluted to 1X solution in methanol. Fresh dilutions
were made for each experiment. Ellagic acid was dissolved in DMSO for a final concentration of
4 mM. The same concentration of 4 mM was prepared for solutions of ferrostatin-1 and ascorbic
acid separately in DMSO. Then, 10 µL of each of the three solutions was added to one of the 96Well Plate containing 190 µL of methanol, for a final volume of 200 µL and a final concentration
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of 200 µM. From there, 2 fold dilutions were made to obtain final concentrations of 100, 50, 25,
12.5 and 6.25 µM. Incubation was done for 30 min in 25°C, during which UV absorbance at 517
nm was measured using TECAN microplate reader at 5 minute intervals. Percentage of inhibition
in UV absorbance was calculated for each concentration at each time point. Pure methanol was
used for background control of UV measurements. All experiments were repeated 3 times and
data was averaged.

20

Results and discussion

Regeneration studies of RNase A

Figure 10 shows the regeneration profile of fully reduced RNase A. The addition of
tetranitromethane (10µM final concentration) negatively affected the regeneration kinetics,
shown as decreases in native-structure fractions formed over time, and consequent decreases in
the oxidative folding rate constant. The data shows that the addition of ellagic acid to the
regeneration mixture can rescue the oxidative folding process of RNase A under nitrosative
stress conditions. This is shown by restoration of the regeneration kinetics to higher levels. Table
2 summarizes the values of rate constants for the formation of native RNase A structure under
the applied conditions. The oxidative folding rate constant for RNase A is diminished after the
addition of 10 µM of tetranitromethane (0.041) compared to the regeneration mixture without
tetranitromethane (0.2027). The oxidative folding rate constants were restored to higher levels
upon the addition of 100 µM of ellagic acid (0.2004) to a regeneration mixture containing 10 µM
of tetranitromethane.

Similarly, Figure 10 shows that the regeneration profile of fully reduced RNase A is affected
by oxidative stress conditions. The addition of OHx radicals into the regeneration environment (5
µL/ml) lead to decreases in the regeneration kinetics of RNase A. Data was analyzed as
described above. The data shows that the addition of ellagic acid was able to restore the folding
kinetics under oxidative stress conditions to higher levels and rescue the folding of RNase A to
its native structure. The data in Table 2 shows that the oxidative folding rate constant for RNase
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A is diminished after the addition of 5 µl/ml of the ferrous sulfate / hydrogen peroxide mixture
(0.0278) compared to the regeneration mixture without OHx radicals (0.2027). The oxidative
folding rate constants were restored to higher levels upon the addition of 100 µM of ellagic acid
(0.2016) to a regeneration mixture containing 5 µl/ml of the ferrous sulfate / hydrogen peroxide
mixture.

hours

Figure 10. Regeneration of native RNase A formed from the fully-reduced protein (R). The regeneration
conditions were 40 uM fully-reduced RNase A, 100 mMDTTox, pH 8, 200mM Tris–HCl, 25° C.
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Table 2.
Rate constants of RNase A regeneration under control conditions, under nitrosative stress
conditions, and under oxidative stress conditions (100 mMDTTox, pH 8, 200mM Tris–HCl, 25°
C).
Folding condition

Rate constant R

R

0.2027 ± 0.0049

R + 10µM TNM

0.0410 ± 0.0034

R + 10µM TNM + 100µM ellagic acid

0.2004 ± 0.0032

R + 5µl/ml OHx

0.0278 ± 0.0012

R + 5µl/ml OHx + 100µM ellagic acid

0.2016 ± 0.0025

N

NOx scavenge assays and Mass Spectroscopy.

Figure 11 is the mass spectrum of ellagic acid after incubation in nitrosative stress conditions
(1mM tetranitromethane). The addition of a 90 Da mass to ellagic acid indicates bi-nitration.
Control experiments were done in the absence of tetranitromethane. Results showed the absence
of di-nitro adducts of ellagic acid (Figure 11).
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Figure 11. ESI-FTMS of ellagic acid (1 mM) reaction products after incubation in nitrosative
stress conditions (1mM tetranitromethane).
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1,1-diphenyl-1-picrylhydrazyl assay

UV absorbance at 517 nm is related to the concentration of the antioxidant. As anticipated,
absorbance decreased as the concentration of the antioxidant increased. Figure 12 shows a
comparison of the antioxidant activity of ellagic acid, ferrostatin-1 and ascorbic acid. Observable
color change from purple to yellow was associated with all samples tested. At 5 minutes, the
radical scavenging activity of ellagic acid at 6.25 µM concentration was 41.4%, compared to
35.4% for ferrostatin-1 and 95.6% for ascorbic acid at the same concentration. At concentration
of 200µM, ellagic acid showed radical scavenging activity of 90.8%, compared to 76.8% for
ferrostatin-1 and 95.6% for ascorbic acid at the same concentration. The minimum difference
between radical scavenging activity of ellagic acid and Fer-1 at the 12.5 µM concentration was
observed after 30 minutes, with a difference of 37.4%. The maximum difference in radical
scavenging activity of the same two antioxidants was observed at the same concentration (12.5
µM) at the 10 time point, with a difference of 41.0%.

Previous studies (27-28, 37) revealed that nitrosative stress conditions lead to disruption in the
oxidative folding process of PDI substrate proteins. However, those results were attributed to the
loss of catalytic activity of PDI chaperone through the modification of Cysteine residues of the
PDI chaperone, which are responsible for both its oxidation and isomerization functions.
However, here we demonstrated that increased levels of nitrosative stress had an additional
direct effect on maturation of disulfide-bond-containing proteins, without PDI catalytic activity
being involved in the oxidative folding process. This is demonstrated by the decreased rate of
regeneration of fully reduced RNase A in presence of NOx and OHx radicals, measured by the
folding rate constant. However, the observed rate of regeneration of RNase A in the presence of
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NOx and ellagic acid equaled levels observed in absence of NOx. Similar data shows that the
regeneration kinetics in presence of OHx and ellagic acid are restored to those observed in
absence of OHx. Although the mechanism of action and location of NOx and OHx radicals on
the polyphenols are not investigated here, our study demonstrates that PDI-substrate proteins’
oxidative folding can be maintained unaffected under nitrosative and oxidative stress conditions
as long as the radical-scavenging ellagic acid is present.
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Figure 12. The radical scavenging activity of ellagic acid, ascorbic acid and ferrostatin-1
shown by % inhibition of UV absorbance at 517nm using DPPH assay. Six different
concentrations of each antioxidant were used. Bars’ color gradient, from darker to lighter,
represents concentration gradient, from the highest to the lowest. Measurements were done at six
different time points, with 5 minute intervals between each.
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Conclusion

Increased levels of nitrosative stress intracellularly within the endoplasmic reticulum is a key
factor involvled in the pathogenesis of both Parkinson's (PD) and Alzheimer's (AD) diseases.
Previous in-vitro studies in our lab showed that increased levels of nitrosative stress lead to
aggregation of misfolded proteins and formation of Lewy Bodies, the main biomarker of PD and
AD diseases. Although this was mainly through nitrosylation of Protein Disulfide Isomerase
(PDI), the chief endoplasmic reticulum (ER) resident oxidoreductase chaperone responsible for
maturation of disulfide-bond-containing proteins, we demonstrate in this paper that increased
levels of nitrosative stress has an additional direct effect on maturation of disulfide-bond
containing proteins. Importantly, we demonstrate that the maturation of disulfide-containing
proteins under conditions mimicking nitrosative stress can be rescued by the naturally occurring
ellagic acid. Our data reveals that ellagic acid can serve as a lead prophylactic agent in searching
for

small

molecules

that

can

prevent

against

oxidative/nitrosative

stress-related

neurodegenerative diseases.
Our future scope for the study is investigating the neuroprotective effect of ellagic acid in
green-fluorescent protein-tagged synphilil-1 in dopaminergic neural cell line. Synphilin-1 is a
conistituent of lewy bodies aggregations noticed in the cytosol of human neural cells. It is
considered a main biomarker of Parkinson’s Disease. Expected positive results will be represented
by decreased Synphilin-1 aggregation in the cytosol of neural cell lines exposed to oxidative stress
conditions after incubation with ellagic acid. This will open the way for taking the antioxidant
molecule, ellagic acid, for the next step by investigating it’s neuroprotective effect in animal
models, and from there to clinical studies in humans. This work opens avenues for the design of
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new prophylactic agents that are less toxic and more effective against neurodegenerative diseases,
including Alzheimer’s disease and Parkinson’s Disease.
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